'''Flesinoxan''' ('''DU-29,373''') is a [[potency (pharmacology)|potent]] and [[binding selectivity|selective]] [[5-HT1A receptor|5-HT<sub>1A</sub> receptor]] [[partial agonist|partial]]/near-[[full agonist|full]] [[receptor agonist|agonist]] of the [[phenylpiperazine]] class.<ref name="pmid3207999">{{cite journal |vauthors=Schoeffter P, Hoyer D | title = Centrally acting hypotensive agents with affinity for 5-HT1A binding sites inhibit forskolin-stimulated adenylate cyclase activity in calf hippocampus. | journal = Br J Pharmacol. | volume = 95 | issue = 3 | pages = 975–985 | year = 1988 | pmid = 3207999 | pmc = 1854240 | doi=10.1111/j.1476-5381.1988.tb11728.x}}</ref><ref name="pmid15013031">{{cite journal |vauthors=Pitchot W, Wauthy J, Legros JJ, Ansseau M | title = Hormonal and temperature responses to flesinoxan in normal volunteers: an antagonist study | journal = European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology | volume = 14 | issue = 2 | pages = 151–5 |date=March 2004 | pmid = 15013031 | doi = 10.1016/S0924-977X(03)00108-1 | url = }}</ref><ref name="pmid8570029">{{cite journal |vauthors=Hadrava V, Blier P, Dennis T, Ortemann C, de Montigny C | title = Characterization of 5-hydroxytryptamine1A properties of flesinoxan: in vivo electrophysiology and hypothermia study | journal = Neuropharmacology | volume = 34 | issue = 10 | pages = 1311–26 |date=October 1995 | pmid = 8570029 | doi = 10.1016/0028-3908(95)00098-Q| url = http://linkinghub.elsevier.com/retrieve/pii/002839089500098Q}}</ref> Originally developed as a potential [[antihypertensive|antihypertensive drug]],<ref name="pmid3207999" /><ref name="pmid15013031" /><ref name="pmid2842163">{{cite journal |vauthors=Wouters W, Tulp MT, Bevan P | title = Flesinoxan lowers blood pressure and heart rate in cats via 5-HT1A receptors | journal = European Journal of Pharmacology | volume = 149 | issue = 3 | pages = 213–23 |date=May 1988 | pmid = 2842163 | doi = 10.1016/0014-2999(88)90651-6| url = }}</ref> flesinoxan was later found to possess [[antidepressant]] and [[anxiolytic]] effects in animal tests.<ref name="pmid1351303">{{cite journal |vauthors=van Hest A, van Drimmelen M, Olivier B | title = Flesinoxan shows antidepressant activity in a DRL 72-s screen | journal = Psychopharmacology | volume = 107 | issue = 4 | pages = 474–9 | year = 1992 | pmid = 1351303 | doi = 10.1007/BF02245258| url = }}</ref><ref name="pmid7972301">{{cite journal |vauthors=Rodgers RJ, Cole JC, Davies A | title = Antianxiety and behavioral suppressant actions of the novel 5-HT1A receptor agonist, flesinoxan | journal = Pharmacology, Biochemistry, and Behavior | volume = 48 | issue = 4 | pages = 959–63 |date=August 1994 | pmid = 7972301 | doi = 10.1016/0091-3057(94)90205-4| url = http://linkinghub.elsevier.com/retrieve/pii/0091-3057(94)90205-4}}</ref> As a result, it was investigated in several small [[human]] [[pilot experiment|pilot studies]] for the treatment of [[major depressive disorder]], and was found to have robust [[efficacy|effectiveness]] and very good [[tolerability]].<ref name="pmid8263314">{{cite journal |vauthors=Grof P, Joffe R, Kennedy S, Persad E, Syrotiuk J, Bradford D | title = An open study of oral flesinoxan, a 5-HT1A receptor agonist, in treatment-resistant depression | journal = International Clinical Psychopharmacology | volume = 8 | issue = 3 | pages = 167–72 | year = 1993 | pmid = 8263314 | doi = 10.1097/00004850-199300830-00005| url = }}</ref><ref name="Marc Ansseau, William Pitchot, Antonio Gonzalez Moreno, Jacques Wauthy, Patrick Papart 2004 279–283">{{cite journal |author1=Marc Ansseau |author2=William Pitchot |author3=Antonio Gonzalez Moreno |author4=Jacques Wauthy |author5=Patrick Papart | title = Pilot study of flesinoxan, a 5-HT1A agonist, in major depression: Effects on sleep REM latency and body temperature. | journal = Human Psychopharmacology: Clinical and Experimental | volume = 8 | issue = 4 | pages = 279–283 | year = 2004 | url = http://www3.interscience.wiley.com/journal/109710934/abstract | doi = 10.1002/hup.470080407 }}</ref> Unfortunately however, due to "management decisions", the development of flesinoxan was stopped and it was not pursued any further.<ref name="pmid23757185">{{cite journal |vauthors=Celada P, Bortolozzi A, Artigas F | title = Serotonin 5-HT1A receptors as targets for agents to treat psychiatric disorders: rationale and current status of research | journal = CNS Drugs | volume = 27 | issue = 9 | pages = 703–16 |date=September 2013  | pmid = 23757185 | doi = 10.1007/s40263-013-0071-0 | url = }}</ref>
